Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-daily Human GLP-1 Analog, Compared with Glimepiride: All as Monotherapy in Type 2 Diabetes
Abstract Number: 7-LB
Authors: ALAN GARBER, ROBERT HENRY, ROBERT RATNER, PEDRO A. GARCIA-HERNANDEZ, HIROMI M. RODRIGUEZ PATTZI, ISRAEL OLVERA-ALVAREZ, PAULA M. HALE, MILAN ZDRAVKOVIC, BRUCE BODE, Houston, TX, San Diego, CA, Hyattsville, MD, Monterrey, Mexico, Mexico City, Mexico, Princeton, NJ, Bagsvaerd, Denmark, Atlanta, GA
Institutions: Atlanta, GA; Houston, TX; Hyattsville, MD; Princeton, NJ; San Diego, CA
Results: This 52-week randomized trial compared the efficacy and safety of two doses of liraglutide (1.2 and 1.8 mg, QD) to glimepiride (8 mg QD). Subjects were previously treated with diet and exercise (D/E) or previous OAD monotherapy (mono). In total, 746 subjects were randomized (mean age 53.0±10.9); mean body mass index 33.1±5.8 kg/m2, mean HbA1c 8.3±1.1%). Liraglutide 1.2 and 1.8 mg reduced HbA1c more than glimepiride (ANCOVA, p=0.0014 and p<0.0001) and more of the subjects in the liraglutide groups reached HbA1c ≤6.5 and <7.0% (p<0.01 vs. glimepiride). In addition, the decrease in HbA1c with liraglutide 1.8 mg was significantly greater than the decrease with liraglutide 1.2 mg (p=0.0046). At the end of the study, there was significant weight decrease in the liraglutide groups, as compared to weight gain in the glimepiride group. The most common adverse events in the liraglutide groups were gastrointestinal disorders (mainly nausea). Nausea occurred in approximately 29% of subjects in the liraglutide groups, but was transient. The rates of minor hypoglycemic episodes (<56 mg/dL) were significantly lower for the liraglutide groups, vs. glimepiride. No subjects reported major hypoglycemic events. In conclusion, liraglutide monotherapy significantly lowered HbA1c versus glimepiride and, at the same time, resulted in weight loss and lower rates of hypoglycemia.